MCMURRAY, Pa. & CHICAGO–(BUSINESS WIRE)–Mar 19, 2013–StelKast, designer, manufacturer and distributor of a full line of quality orthopedic implants for knee and hip replacement, is celebrating 20 years of innovation with the launch of the “ What’s Next ” initiative at the American Academy of Orthopaedic Surgeons (AAOS) 2013 Annual Meeting. The initiative focuses on regulatory and market changes sweeping the orthopedics industry. StelKast is responding to these changes by partnering with surgeons to ensure that the industry can be successfully reshaped. Surgeons are invited to share their thoughts and concerns at WhatsNextForOrtho.com.
Health care reform will require device makers to embrace innovative new business models that can serve practices and improve patient outcomes, while continuing to deliver quality products.
“A surgeon must always implant the device that will best serve the patient, StelKast understands this and is extremely responsive,” said Robert Good, M.D., Rothman Institute, Chief of Orthopaedic Surgery at Bryn Mawr Hospital of Pennsylvania. “I have used StelKast for two decades and appreciate that while remaining flexible in business they maintain stellar quality standards for patient success.” In addition to being a privately held company, StelKast specializes in design, manufacturing and distribution. This allows for extremely flexible capabilities in working closely with doctors and hospital management to meet the challenges of health care reform by embracing new business models. Including: distribution models, accountable care organizations, bundled payments, surgeon-owned hospitals and surgery centers.
“StelKast was established as a surgeon–centric provider of quality orthopedic implants. The company faced and surmounted every challenge it faced the past twenty years. A proven, time tested product line coupled with flexibility and responsiveness, unimpeded by size, makes StelKast the right choice for surgeons and hospitals,” said Peter Stephans, Chairman and CEO of StelKast. “The ‘What’s Next’ initiative will help shape the future of our industry and keep the focus on surgeons and improving patient outcomes.” Today’s announcement from StelKast is a continuation of innovation and industry leadership. StelKast was the first to introduce titanium to orthopedics in the 70’s. With over 40 years of experience manufacturing high quality precision parts in the regulated medical and aerospace industries, StelKast’s parent company has a history of excellence.
StelKast specializes in the design, manufacture, and distribution of hip and knee implant systems. The Company’s mission is to provide high-quality, cost effective solutions to meet the challenges of the orthopedic community through clinically proven design concepts and innovative technology. For more information about StelKast, please visit the company website at www.stelkast.com.